Robuta

https://www.panabee.com/idea/is-palladyne-ai-pdyn-a-buy-03052026 Is Palladyne AI (PDYN) a Buy? | Mar 05 2026 Is Palladyne AI (PDYN) a Buy? | Mar 05 2026: Palladyne AI pivots to defense manufacturing via acquisitions, projecting 2026 revenue of $24M-$27M. Upside hinges... buy marai https://www.panabee.com/idea/is-intuitive-machines-lunr-a-buy-03232026 Is Intuitive Machines (LUNR) a Buy? | Mar 23 2026 Is Intuitive Machines (LUNR) a Buy? | Mar 23 2026: Intuitive Machines acquired Lanteris, creating an end-to-end space prime with a ~$943M backlog and $900M-$1B... buy marintuitivemachineslunr https://www.panabee.com/idea/is-satellogic-satl-a-buy-03232026 Is Satellogic (SATL) a Buy? | Mar 23, 2026 Is Satellogic (SATL) a Buy? | Mar 23, 2026: Satellogic (SATL) saw 94% YoY Q4 revenue growth and has a $129M balance sheet after its US relocation. However,... buy marsatellogic https://www.panabee.com/idea/is-hims-and-hers-a-buy-03092026 Is Hims & Hers (HIMS) a Buy? | Mar 09 2026 buy marhims https://www.panabee.com/idea/is-alto-ingredients-alto-a-buy-03052026 Is Alto Ingredients (ALTO) a Buy? | Mar 05 2026 Mar 5, 2026 - Q4 2025 net income swung positive on crush margins and 45Z tax credits. Bulls see structural margin improvement from the liquid CO2 business. Bears highlight... buy maraltoingredients https://www.panabee.com/idea/is-relmada-therapeutics-rlmd-a-buy-03092026 Is Relmada Therapeutics (RLMD) a Buy? | Mar 09 2026 Is Relmada Therapeutics (RLMD) a Buy? | Mar 09 2026: Relmada Therapeutics pivoted to oncology, with its bladder cancer drug NDV-01 showing a 76% 12-month... buy martherapeutics https://www.panabee.com/idea/is-marvell-technology-a-buy-03062026 Is Marvell Technology (MRVL) a Buy? | Mar 06 2026 Is Marvell Technology (MRVL) a Buy? | Mar 06 2026: Marvell, a fabless semi, reported record Q4 revenue ($2.22B) and a $1.5B AI ASIC run-rate, fueling... buy marmarvelltechnology https://www.panabee.com/idea/is-turning-point-brands-tpb-a-buy-03022026 Is Turning Point Brands (TPB) a Buy? | Mar 02, 2026 Is Turning Point Brands (TPB) a Buy? | Mar 02, 2026: Turning Point Brands (TPB) is pivoting to modern oral nicotine, with white pouch sales growing 266%. This... turning pointbuy marbrandstpb https://www.panabee.com/idea/is-applied-optoelectronics-aaoi-a-buy-03242026 Is Applied Optoelectronics (AAOI) a Buy? | Mar 24 2026 Mar 24, 2026 - Applied Optoelectronics has strong momentum with $250M in new hyperscaler orders and 83% YoY revenue growth. However, persistent unprofitability, heavy insider... buy marappliedoptoelectronics https://www.panabee.com/idea/is-samsara-iot-a-buy-03062026 Is Samsara (IOT) a Buy? | Mar 06 2026 Is Samsara (IOT) a Buy? | Mar 06 2026: Samsara buy marsamsaraiot https://www.panabee.com/idea/is-idaho-copper-copr-a-buy-03212026 Is Idaho Copper (COPR) a Buy? | Mar 21 2026 Mar 21, 2026 - Pre-revenue Idaho Copper (COPR) faces a liquidity crisis with a $4.59M deficit and defaulted notes. An upsized $15M NYSE IPO is critical to survive, fund an... buy maridahocopper https://www.panabee.com/idea/is-fastly-fsly-a-buy-03232026 Is Fastly (FSLY) a Buy? | Mar 23 2026 Mar 23, 2026 - Fastly achieved its first profitable year, driven by AI workloads and 32% security revenue growth. However, 2026 guidance implies a growth deceleration to 14%,... buy marfastly https://www.panabee.com/idea/is-expedia-a-buy-03052026 Is Expedia (EXPE) a Buy? | Mar 05 2026 buy marexpedia https://www.panabee.com/idea/is-arm-holdings-arm-a-buy-03252026 Is Arm Holdings (ARM) a Buy? | Mar 25 2026 Mar 25, 2026 - Arm Holdings is pivoting from IP licensing to selling its own data center chips, securing Meta as an anchor customer. This strategy expands its market but... arm holdingsbuy mar https://www.panabee.com/idea/is-papa-johns-a-buy-03112026 Is Papa John's (PZZA) a Buy? | Mar 11 2026 papa johnbuy mar https://www.panabee.com/idea/is-adma-biologics-adma-a-buy-03272026 Is ADMA Biologics (ADMA) a Buy? | Mar 27 2026 Mar 27, 2026 - ADMA Biologics faces short-seller allegations of channel stuffing, causing a 29% stock decline. Bulls point to its vertically integrated model, 57.4% gross... buy maradmabiologics https://www.panabee.com/idea/is-pfizer-pfe-a-buy-03212026 Is Pfizer (PFE) a Buy? | Mar 21 2026 Is Pfizer (PFE) a Buy? | Mar 21 2026: Pfizer navigates declining COVID revenues and looming patent cliffs for Ibrance and Xtandi. The bull case rests on the... buy marpfizerpfe https://www.panabee.com/idea/is-argan-agx-a-buy-03272026 Is Argan (AGX) a Buy? | Mar 27 2026 Mar 27, 2026 - Argan, Inc. has a record $2.9B backlog and expanding 25% gross margin, driven by AI-related electricity demand. However, over $40M in recent insider selling... buy mararganagx https://www.panabee.com/idea/is-corcept-therapeutics-cort-a-buy-03252026 Is Corcept Therapeutics (CORT) a Buy? | Mar 25, 2026 Mar 25, 2026 - Corcept Therapeutics won early FDA approval for its oncology drug Lifyorli. However, its primary $761M revenue stream, Korlym, faces imminent generic... buy martherapeuticscort https://www.panabee.com/idea/is-iovance-biotherapeutics-iova-a-buy-03062026 Is Iovance Biotherapeutics (IOVA) a Buy? | Mar 06 2026 Is Iovance Biotherapeutics (IOVA) a Buy? | Mar 06 2026: Iovance has a validated cell therapy platform showing a 50% response rate in difficult sarcomas,... buy marbiotherapeutics https://www.panabee.com/idea/is-ocular-therapeutix-ocul-a-buy-03022026 Is Ocular Therapeutix (OCUL) a Buy? | Mar 02 2026 buy maroculartherapeutix https://www.panabee.com/idea/is-axt-axti-a-buy-03022026 Is AXT (AXTI) a Buy? | Mar 02 2026 Mar 2, 2026 - AXT, Inc. supplies critical indium phosphide for AI optics, holding a record $60M backlog and $128.4M cash to double capacity. However, total reliance on... buy maraxt https://www.panabee.com/idea/is-poet-technologies-poet-a-buy-03022026 Is POET Technologies (POET) a Buy? | Mar 02 2026 Mar 2, 2026 - Pre-profit POET has $5.6M in initial orders for its AI-focused optical engines. However, risks include severe shareholder dilution, with shares doubling in a... buy marpoettechnologies https://www.panabee.com/idea/is-kala-bio-a-buy-03112026 Is Kala Bio (KALA) a Buy? | Mar 11 2026 Mar 11, 2026 - Kala Bio (KALA) pivoted from a failed biotech to licensing AI software. With a strained balance sheet ($21M cash, $28M debt), it faces insolvency risk. Bulls... buy markalabio https://www.panabee.com/idea/is-tango-therapeutics-tngx-a-buy-03052026 Is Tango Therapeutics (TNGX) a Buy? | Mar 05 2026 buy martangotherapeutics https://www.panabee.com/idea/is-kodiak-sciences-a-buy-03262026 Is Kodiak Sciences (KOD) a Buy? | Mar 26 2026 Is Kodiak Sciences (KOD) a Buy? | Mar 26 2026: Kodiak buy markodiaksciences https://www.panabee.com/idea/is-firefly-aerospace-fly-a-buy-03312026 Is Firefly Aerospace (FLY) a Buy? | Mar 31 2026 Mar 31, 2026 - Firefly Aerospace has a $1.35B backlog and ~$793M in cash after a successful return-to-flight. However, it faces execution risk with its new Alpha Block II... firefly aerospacebuy mar https://www.panabee.com/idea/is-alkermes-a-buy-03312026 Is Alkermes (ALKS) a Buy? | Mar 31, 2026 Is Alkermes (ALKS) a Buy? | Mar 31, 2026: Alkermes acquired Avadel, adding $1.5B in debt but gaining commercial sleep drug Lumryz. Its orexin agonist pipeline... buy maralkermes